FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Anergy topics
Immune Response
Expression Vector
Cancer Cells
Cancer Cell
Transcription
Polypeptide
Lymphocyte
Intracellular
Immune System
Macrophage
Dendritic Cell
Dissociation
Antagonist
Type I Diabetes
Rheumatoid Factor

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Anergy patents



      
           
This page is updated frequently with new Anergy-related patent applications. Subscribe to the Anergy RSS feed to automatically get the update: related Anergy RSS feeds. RSS updates for this page: Anergy RSS RSS


Date/App# patent app List of recent Anergy-related patents
08/14/14
20140227262
 Pd-1 antagonists and methods for treating infectious disease patent thumbnailPd-1 antagonists and methods for treating infectious disease
Methods and compositions for treating an infection or disease that results from (1) failure to elicit rapid t cell mediated responses, (2) induction of t cell exhaustion, t cell anergy or both, or (3) failure to activate monocytes, macrophages, dendritic cells and/or other apcs, for example, as required to kill intracellular pathogens. The method and compositions solve the problem of undesired t cell inhibition by binding to and blocking pd-1 to prevent or reduce inhibitory signal transduction, or by binding to ligands of pd-1 such as pd-l1, thereby preventing (in whole or in part) the ligand from binding to pd-1 to deliver an inhibitory signal.
03/13/14
20140073045
 Mucin antigen vaccine patent thumbnailMucin antigen vaccine
Provided are expression vectors for generating an immune response to a mucin. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal, a mucin antigen and cd40 ligand.
01/16/14
20140017218
 Method for inducing immune tolerance using viable polymer-modified allogeneic leukocytes patent thumbnailMethod for inducing immune tolerance using viable polymer-modified allogeneic leukocytes
This invention relates to cellular-based therapies for increasing the level of regulatory t cells (treg) and/or decreasing the level of pro-inflammatory t cells (th17) to induce anergy or immune tolerance. To provide these therapeutic effects, two allogeneic leukocyte populations are contacted (in vivo, in vitro or ex vivo) and one of these leukocyte population is modified to bear on its surface a low-immunogenic biocompatible polymer so as to prevent pro-inflammatory allo-recognition.
12/12/13
20130330294
 Serum amyloid a (saa) overrides regulatory t cells (treg) anergy patent thumbnailSerum amyloid a (saa) overrides regulatory t cells (treg) anergy
Methods and compositions are provided for inducing the proliferation of regulatory t cells. These methods find a number of uses, including, for example, treating autoimmune and rheumatoid diseases.
04/25/13
20130101626
 Mucin antigen vaccine patent thumbnailMucin antigen vaccine
Provided are expression vectors for generating an immune response to a mucin. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal, a mucin antigen and cd40 ligand.
02/14/13
20130039935
 Induction of tumor immunity by variants of folate binding protein patent thumbnailInduction of tumor immunity by variants of folate binding protein
The present invention is directed to variants of antigens comprising folate binding protein epitopes as a composition associated with providing immunity against a tumor in an individual. The variant is effective in inducing cytotoxic t-lymphocytes but preferably not to the extent that they become sensitive to silencing by elimination, such as by apoptosis, or by anergy, as in unresponsiveness..
01/17/13
20130017199
 Simultaneous inhibition of pd-l1/pd-l2 patent thumbnailSimultaneous inhibition of pd-l1/pd-l2
Methods and compositions for treating an infection or disease that results from (1) failure to elicit rapid t cell mediated responses, (2) induction of t cell exhaustion, t cell anergy or both, or (3) failure to activate monocytes, macrophages, dendritic cells and/or other apcs, for example, as required to kill intracellular pathogens. The method and compositions solve the problem of undesired t cell inhibition by simultaneously inhibiting the pd-1 ligands, pd-l1 and pd-l2.


Popular terms: [SEARCH]

Anergy topics: Immune Response, Expression Vector, Cancer Cells, Cancer Cell, Transcription, Polypeptide, Lymphocyte, Intracellular, Immune System, Macrophage, Dendritic Cell, Dissociation, Antagonist, Type I Diabetes, Rheumatoid Factor

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Anergy for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Anergy with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



0.079

293

2 - 1 - 7